{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:40:21Z","timestamp":1793932821799,"version":"4.8.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002108","name":"FARA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jns.2024.123053","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T15:12:52Z","timestamp":1715699572000},"page":"123053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Characterization of clinical serum cardiac biomarker levels in individuals with Friedreich ataxia"],"prefix":"10.1016","volume":"461","author":[{"given":"David R.","family":"Lynch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hearle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Greeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gunther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medina","family":"Keita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Strawser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Schadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly Y.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123053_bb0005","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archneur.59.5.743","article-title":"Wilson RB Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy","volume":"59","author":"Lynch","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2024.123053_bb0010","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1001\/archneur.65.10.1296","article-title":"Friedreich ataxia","volume":"65","author":"Pandolfo","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2024.123053_bb0015","article-title":"Friedreich ataxia- pathogenesis and implications for therapies","volume":"132","author":"Bidichandani","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2024.123053_bb0020","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/hmg\/7.9.1485","article-title":"Maturation of wild-type and mutated frataxin by the mitochondrial processing peptidase","volume":"7","author":"Koutnikova","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jns.2024.123053_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","article-title":"Friedreich\u2019s ataxia: pathology, pathogenesis, and molecular genetics","volume":"303","author":"Koeppen","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123053_bb0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/brain\/104.3.589","article-title":"Friedreich\u2019s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and interfamilial clustering of clinical features","volume":"104","author":"Harding","year":"1981","journal-title":"Brain"},{"key":"10.1016\/j.jns.2024.123053_bb0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/bmb\/ldx034","article-title":"Friedreich\u2019s ataxia: clinical features, pathogenesis and management","volume":"124","author":"Giunti","year":"2017","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.jns.2024.123053_bb0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","article-title":"Mortality in Friedreich ataxia","volume":"307","author":"Tsou","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123053_bb0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/hrt.31.1.5","article-title":"The heart in Friedreich\u2019s ataxia","volume":"31","author":"Hewer","year":"1969","journal-title":"Br. Heart J."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2024.123053_bb0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jnc.12217","article-title":"Cardiomyopathy of Friedreich ataxia","volume":"126","author":"Weidemann","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2024.123053_bb0055","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s11845-012-0808-7","article-title":"Cardiomyopathy of Friedreich\u2019s ataxia (FRDA)","volume":"181","author":"Payne","year":"2012","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.jns.2024.123053_bb0060","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/erc.12.57","article-title":"Management and therapy for cardiomyopathy in Friedreich\u2019s ataxia","volume":"10","author":"Lynch","year":"2012","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.jns.2024.123053_bb0065","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/0883073812448461","article-title":"Cross-sectional analysis of electrocardiograms in a large heterogeneous cohort of Friedreich Ataxia subjects","volume":"27","author":"Schadt","year":"2012","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.jns.2024.123053_bb0070","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00246-008-9305-1","article-title":"The longitudinal course of cardiomyopathy in Friedreich\u2019s ataxia during childhood","volume":"30","author":"Kipps","year":"2009","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.jns.2024.123053_bb0075","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0735-1097(00)00804-4","article-title":"Myocardial infarction redefined \u2014 a consensus document of the joint European Society of Cardiology\/ American College of Cardiology Committee for the redefinition of myocardial infarction","volume":"36","author":"Alpert","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jns.2024.123053_bb0080","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.ijcard.2012.04.159","article-title":"Elevation of serum cardiac troponin I in a cross-sectional cohort of asymptomatic subjects with Friedreich Ataxia","volume":"167","author":"Friedman","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.jns.2024.123053_bb0085","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/jcm9061630","article-title":"Significance of NT-proBNP and high-sensitivity troponin in Friedreich Ataxia","volume":"9","author":"Legrand","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jns.2024.123053_bb0090","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s00246-021-02675-1","article-title":"Myocardial perfusion Reserve in Children with Friedreich Ataxia","volume":"42","author":"Hutchens","year":"2021","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.jns.2024.123053_bb0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.acvd.2021.10.010","article-title":"Characterizing cardiac phenotype in Friedreich\u2019s ataxia: the CARFA study","volume":"115","author":"Legrand","year":"2022","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.jns.2024.123053_bb0100","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/acn3.332","article-title":"Progression of Friedreich ataxia: quantitative characterization over 5 years","volume":"3","author":"Patel","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jns.2024.123053_bb0105","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1212\/01.wnl.0000218155.46739.90","article-title":"Measuring Friedreich ataxia: complementary features of examination and performance measures","volume":"66","author":"Lynch","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123053_bb0110","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mds.22912","article-title":"Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design","volume":"25","author":"Friedman","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2024.123053_bb0115","doi-asserted-by":"crossref","first-page":"11520","DOI":"10.1177\/0883073812448462","article-title":"Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants","volume":"27","author":"Regner","year":"2012","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.jns.2024.123053_bb0120","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/01.CIR.0000025242.79963.4C","article-title":"B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (BNP) multinational study","volume":"106","author":"McCullough","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2024.123053_bb0125","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaneurol.2015.1855","article-title":"A 22-year follow-up study of long-term cardiac outcome and predictors of survival in Friedreich Ataxia","volume":"72","author":"Pousset","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2024.123053_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40256-019-00375-z","article-title":"Predictors of left ventricular dysfunction in Friedreich\u2019s Ataxia in a 16-year observational study","volume":"20","author":"Legrand","year":"2020","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.jns.2024.123053_bb0135","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/mus.27522","article-title":"Serum cardiac troponin I is a candidate biomarker for cardiomyopathy in Duchenne and Becker muscular dystrophies","volume":"65","author":"Yamaguchi","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2024.123053_bb0140","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/s41390-021-01682-5","article-title":"Duchenne muscular dystrophy patients: troponin leak in asymptomatic and implications for drug toxicity studies","volume":"92","author":"Sheybani","year":"2022","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.jns.2024.123053_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001592","article-title":"Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel","volume":"8","author":"Spurney","year":"2021","journal-title":"Open Heart."},{"key":"10.1016\/j.jns.2024.123053_bb0150","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.braindev.2007.01.009","article-title":"Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients","volume":"29","author":"Matsumura","year":"2007","journal-title":"Cardiac Brain Dev."},{"key":"10.1016\/j.jns.2024.123053_bb0155","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1002\/ehf2.14073","article-title":"Blood-based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta-analysis","volume":"9","author":"Jansen","year":"2022","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.jns.2024.123053_bb0160","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2217\/bmm-2021-0022","article-title":"Alteration of serum biomarkers in patients with hypertrophic cardiomyopathy with and without atrial fibrillation","volume":"15","author":"Sari","year":"2021","journal-title":"Biomark. Med."},{"key":"10.1016\/j.jns.2024.123053_bb0165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2021.04.040","article-title":"Usefulness of High-Sensitivity Cardiac Troponin T to Predict Long-Term Outcome in Patients with Hypertrophic Cardiomyopathy","volume":"152","author":"Gommans","year":"2021","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.jns.2024.123053_bb0170","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1038\/s41598-021-83678-z","article-title":"Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep."},{"key":"10.1016\/j.jns.2024.123053_bb0175","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s00246-021-02675-1","article-title":"Myocardial perfusion Reserve in Children with Friedreich Ataxia","volume":"42","author":"Hutchens","year":"2021","journal-title":"Pediatr. Cardiol."},{"key":"10.1016\/j.jns.2024.123053_bb0180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijcard.2015.05.074","article-title":"The cardiomyopathy in Friedreich\u2019s ataxia \u2013 new biomarker for staging cardiac involvement","volume":"194","author":"Weidemann","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.jns.2024.123053_bb0185","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0008-6363(01)00357-1","article-title":"Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study","volume":"52","author":"Lodi","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jns.2024.123053_bb0190","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/84818","article-title":"Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits","volume":"27","author":"Puccio","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jns.2024.123053_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.653241","article-title":"The role of serum levels of Neurofilament light (NfL) chain as a biomarker in Friedreich Ataxia","volume":"15","author":"Frempong","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jns.2024.123053_bb0200","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1007\/s00415-020-09868-3","article-title":"Neurofilament light chain as a potential biomarker of disease status in Friedreich ataxia","volume":"267","author":"Clay","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2024.123053_bb0205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00395-015-0517-2","article-title":"Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy","volume":"110","author":"Haghikia","year":"2015","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.jns.2024.123053_bb0210","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.106.635664","article-title":"Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium","volume":"114","author":"G\u00f6ser","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2024.123053_bb0215","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clim.2009.04.008","article-title":"Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure","volume":"134","author":"Kaya","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jns.2024.123053_bb0220","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2021.11.033","article-title":"Cellular pathophysiology of Friedreich\u2019a Ataxia cardiomyopathy","volume":"346","author":"Lees","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.jns.2024.123053_bb0225","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1093\/hmg\/ddy198","article-title":"Peripheral blood gene expression reveals an inflammatory transcriptomic signature in Friedreich\u2019s ataxia patients","volume":"27","author":"Nachun","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jns.2024.123053_bb0230","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/mus.26610","article-title":"Open-label pilot study of oral methylprednisolone for the treatment of patients with Friedreich ataxia","volume":"60","author":"Patel","year":"2019","journal-title":"Muscle Nerve"},{"issue":"21","key":"10.1016\/j.jns.2024.123053_bb0235","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1161\/CIRCULATIONAHA.111.023697","article-title":"How to interpret elevated cardiac troponin levels","volume":"124","author":"Mahajan","year":"2011","journal-title":"Circulation"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:30:45Z","timestamp":1736184645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24001886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":47,"alternative-id":["S0022510X24001886"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123053","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of clinical serum cardiac biomarker levels in individuals with Friedreich ataxia","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123053"}}